Biotechnology Instruments Market

On 7 February 2025 the US National Institutes of Health capped the indirect costs it pays universities at 15% of a grant, and within weeks academic core facilities across the United States froze orders for sequencers, cytometers and microscopes. Courts blocked the cap in March and April 2025, and the 1st Circuit Court of Appeals struck it down on 6 January 2026, but the pause split the biotechnology instruments market in two: bioprocess equipment kept growing with biologics production while research instruments stalled. Douglas Insights values the biotechnology instruments market at USD 41.6 billion in 2025 and expects USD 75.7 billion by 2035, a compound annual growth rate of 6.18%. The build is bottom-up: about 452,000 instruments shipped in 2025 at an average realised price of USD 92,000, from USD 15,000 benchtop centrifuges to USD 6 million cryo-electron microscopes. Units grow 4.3% a year as biologics plants, cell therapy suites and Asian research institutes are equipped, and the average price rises 1.8% a year as buyers move to automated, higher-throughput systems. This study sits within our life science instruments coverage and follows the published Douglas Insights methodology.

Which lab and plant systems count as biotechnology instruments?

A biotechnology instrument is capital equipment used to study, engineer or manufacture biological molecules and cells, sold to laboratories and production plants as a system with a serial number. The biotechnology instruments market covers seven categories: genomics instruments such as DNA sequencers, PCR, qPCR and digital PCR systems; chromatography and mass spectrometry systems used to characterise proteins, peptides and metabolites; bioprocess instruments such as bioreactors, chromatography skids, filtration and fill systems and process analytics; cell analysis instruments such as flow cytometers, cell imagers and single-cell platforms; microscopy and imaging systems from confocal to cryo-electron microscopes; lab automation and liquid handling; and spectroscopy and other instruments including spectrophotometers, interaction analysers, osmometers and centrifuges. Consumables, reagents, kits, software subscriptions and service contracts are excluded, as are clinical diagnostic analysers sold to hospital laboratories. Narrower instrument markets that sit inside this boundary, such as the Surface Plasmon Resonance Market and the Osmometer Market, are sized separately in more detail. Value is measured at the manufacturer’s realised price for the instrument.

How do research and bioprocess biotechnology instruments differ as businesses?

Research and bioprocess biotechnology instruments differ in who pays, how often they buy and what makes them switch. A research instrument, such as a flow cytometer in a university immunology core or a sequencer in a discovery lab, is bought from a grant or an R&D budget, often by a committee of scientists who compare specifications and demonstrations; the typical order is one to three systems, the decision takes 3 to 9 months, and the buyer can switch brands at the next replacement because published methods travel between platforms. A bioprocess instrument, such as a 2,000-litre single-use bioreactor, a chromatography skid or an inline analyser, is bought from a capital project budget when a plant is designed, often 12 to 24 months before the first batch, in orders of 10 to 40 units per facility. Once the process is filed with the FDA or the European Medicines Agency, changing an instrument means revalidation and sometimes a regulatory variation, so the platform typically stays for the life of the product, which can exceed 15 years. That is why bioprocess instruments earned 18% of biotechnology instrument value in 2025 but a larger share of the market’s growth: Douglas Insights attributes about 27% of the added value between 2025 and 2035 to bioprocess equipment. It is also why the 7 February 2025 NIH cap hit research instruments and left bioprocess orders almost untouched, and why the two halves of the market can move in opposite directions in the same year.

How do GMP qualification rules and export controls shape biotechnology instrument purchases?

Biotechnology instrument purchases are shaped first by manufacturing rules, because an instrument used to make or release a medicine must be qualified before its data count. In Europe, the good manufacturing practice rules in EudraLex Volume 4, including Annex 1 on sterile products, which applied from 25 August 2022, and Annex 15 on qualification and validation, require every bioreactor, filling line and analyser in a GMP suite to pass installation, operational and performance qualification. In the United States, 21 CFR Part 11 sets the rules for electronic records and signatures, so instrument software without audit trails cannot be used in regulated work. Qualification adds 10% to 20% to the installed cost of a GMP instrument, and it is why a plant rarely switches supplier once a platform is validated. Trade rules are the second layer: in January 2025 the US Bureau of Industry and Security placed export controls on certain high-parameter flow cytometers and liquid chromatography mass spectrometry systems used in biotechnology, and on 4 March 2025 China’s Ministry of Commerce barred Illumina from exporting sequencers into China, which accelerated the shift to domestic sequencers from MGI Tech. Research funding rules are the third: the 7 February 2025 NIH cap showed how quickly a change in grant overhead reaches instrument orders.

What drives biotechnology instrument orders from biologics plants and discovery labs?

Biologics manufacturing is the first driver and the fastest. Monoclonal antibodies, GLP-1 peptides, vaccines and cell and gene therapies all need bioreactors, purification skids and in-process analytics, and every new plant is equipped from scratch. Danaher’s Biotechnology segment, home to Cytiva, grew 8.0% in 2025 to USD 7.3 billion while its research-focused Life Sciences segment was flat at USD 7.3 billion, according to its full-year 2025 results. Douglas Insights models bioprocess instruments growing 8.4% a year from USD 7.49 billion, the fastest of the seven categories. A single 2,000-litre biologics suite needs 6 to 12 bioreactors plus purification and analytics, so each new plant adds USD 20 million to USD 60 million of instrument orders before its first batch.

Pharmaceutical R&D spending is the second driver. Large drug makers spent more than USD 250 billion on research in 2025, and discovery labs buy mass spectrometers, cell imagers and automated liquid handlers to raise throughput per scientist. Thermo Fisher’s Life Sciences Solutions segment grew 7.7% to USD 10.4 billion in 2025, while its Analytical Instruments segment grew 1.2% to USD 7.55 billion, as reported in its fourth quarter and full year 2025 results; the gap shows pharma-led demand outrunning academic and industrial buyers.

Laboratory automation is the third driver. A liquid handler that runs overnight replaces two to three technician shifts, and labs facing staff shortages in the United States, Europe and Japan are automating sample preparation, PCR set-up and cell culture. Douglas Insights models lab automation and liquid handling growing 7.0% a year from USD 3.74 billion, and the same trend lifts average instrument prices by 1.8% a year because integrated systems cost more than the manual benches they replace.

Asian research capacity is the fourth driver. China, India, South Korea and Singapore are building national biotech hubs, and domestic suppliers such as MGI Tech in sequencing are winning share under local procurement preferences. Asia Pacific biotechnology instrument sales grow 7.86% a year, faster than any other region. Genomics is the fifth driver: sequencing cost per human genome has fallen to about USD 200 on the newest platforms, which moves sequencing into population studies, oncology research and agricultural breeding and lifts genomics instrument value from USD 9.56 billion at 5.9% a year.

What slows biotechnology instrument orders after the NIH overhead shock?

Academic funding risk is the first restraint on the biotechnology instruments market. Academic and government labs buy 24% of instrument value, USD 9.98 billion in 2025, and the NIH cap of 7 February 2025 showed how fast they stop buying when overhead is threatened; proposed cuts to the NIH budget in the 2026 appropriations cycle keep that risk alive even after the 6 January 2026 appeals ruling. The slower scenario holds academic unit growth near zero through 2027.

Geopolitics is the second restraint. China accounted for roughly 15% of global instrument sales before 2023, and the combination of US export controls, China’s March 2025 action against Illumina, anti-corruption campaigns in Chinese hospitals and tariffs has pushed Chinese buyers toward domestic suppliers, removing 1 to 2 points of growth a year from Western vendors’ China sales. Biopharma funding cycles are the third: venture funding for biotech start-ups fell by more than 30% from its 2021 peak, and small biotechs buy instruments only after a financing round, so a weak year for funding delays orders by 6 to 12 months. Long replacement cycles are the fourth: a mass spectrometer or flow cytometer runs for 7 to 10 years, so installed-base replacement adds only about 10% to 14% of units in any year.

Bioprocess capacity risk is a fifth, newer restraint. Several CDMOs and drug makers announced biologics and GLP-1 plants between 2023 and 2025, and if demand for a blockbuster slows or a pricing reform cuts margins, projects are deferred; a one-year delay across announced capacity removes about USD 600 million of bioprocess instrument orders from the year it hits, which the slower scenario applies. Vendor pricing discipline limits the damage in a downturn, because instrument makers prefer to hold list prices and offer bundled consumable contracts rather than cut the price of the system itself.

Which biotechnology instrument category, from sequencers to cryo-EM, carries the value?

Genomics instruments carry the most value in the biotechnology instruments market, at 23% of 2025 sales, and bioprocess instruments grow fastest. Douglas Insights values the seven categories as follows.

Genomics instruments are worth USD 9.56 billion because sequencers and PCR systems sit in almost every biotech, academic and contract lab.

Chromatography and mass spectrometry are worth USD 8.73 billion, because every biologic must be characterised for identity, purity and glycosylation before release, which makes these systems the standard analytical backbone.

Bioprocess instruments are worth USD 7.49 billion, and their share rises every year that new biologics and GLP-1 capacity is built.

Cell analysis instruments are worth USD 5.82 billion, led by flow cytometers and single-cell platforms used in immunology and cell therapy release testing.

Microscopy and imaging are worth USD 4.16 billion, where a single cryo-electron microscope can cost USD 5 million to USD 7 million and structural biology centres buy them in clusters.

Lab automation and liquid handling are worth USD 3.74 billion, bought to replace technician hours rather than to add new measurements.

Spectroscopy and other instruments are worth USD 2.08 billion, a mature group of spectrophotometers, interaction analysers, osmometers and centrifuges that grows slowest.

Do drug makers, universities or CDMOs buy more biotechnology instruments?

Pharmaceutical and biotechnology companies buy 52% of biotechnology instruments by value, USD 21.6 billion in 2025, across discovery, development and manufacturing. Academic and government research institutes buy 24%, USD 9.98 billion, and are the most exposed to funding shocks. Contract development and manufacturing organisations and contract research organisations buy 14%, USD 5.82 billion, and grow fastest among buyers at about 8% a year as drug makers outsource production; the Cell and Gene Therapy CDMO Services Market report shows how quickly one part of that capacity is being built. Agricultural, food, industrial biotechnology and hospital research labs buy the remaining 10%, USD 4.16 billion.

What price does a biotechnology instrument fetch, from a qPCR system to a cryo-electron microscope?

Biotechnology instruments are priced as capital equipment, and Douglas Insights puts the 2025 average at USD 92,000 per system across all seven categories. A benchtop qPCR system sells for USD 20,000 to USD 60,000, while a high-throughput production sequencer lists near USD 1 million. A triple-quadrupole or high-resolution LC-MS system costs USD 250,000 to USD 600,000, a spectral flow cytometer USD 150,000 to USD 400,000, and an automated liquid handler USD 60,000 to USD 300,000 depending on channels and integration. At the top end, a 2,000-litre single-use bioreactor system with controls costs USD 1 million to USD 2 million and a cryo-electron microscope USD 5 million to USD 7 million. Vendors increasingly price instruments close to cost and earn their margin on the consumables and service each system pulls through, which can total two to four times the instrument price over its life; that pull-through is excluded here but explains why vendors fight hard for placements.

Which region buys the most biotechnology instruments, and how fast is Asia Pacific catching up?

North America buys the most biotechnology instruments, 41% of 2025 value or USD 17.0 billion. North America grows 5.6% a year to USD 29.4 billion in 2035, because the United States hosts the largest biopharma R&D budgets, the Boston, San Francisco and San Diego clusters and a wave of reshored biologics plants. Europe buys 27%, USD 11.2 billion, growing 5.3% a year, led by Germany, Switzerland, the United Kingdom, Ireland and Denmark, where GLP-1 and biologics capacity expansions are concentrated. Asia Pacific buys 25%, USD 10.4 billion, and grows fastest at 7.86% a year to USD 22.2 billion, as China builds domestic supply chains, India expands biosimilar and CDMO capacity, and South Korea and Singapore add biologics plants. Latin America buys 4%, USD 1.66 billion, growing 6.0% a year with Brazilian vaccine and biologics production. The Middle East and Africa buy 3%, USD 1.25 billion, and are the wildcard at 6.6% a year: Saudi Arabia and the United Arab Emirates are funding genomics programmes and local vaccine plants from sovereign budgets rather than grants.

Who supplies biotechnology instruments, and how far does Thermo Fisher lead?

The biotechnology instruments market is moderately concentrated: Douglas Insights estimates Thermo Fisher Scientific holds about 14% of 2025 instrument value and the five largest suppliers about 45%. Thermo Fisher leads through the broadest range across mass spectrometry, chromatography, electron microscopy, PCR and bioprocess equipment. Danaher follows through Cytiva in bioprocessing, SCIEX in mass spectrometry, Beckman Coulter Life Sciences in cell analysis and centrifuges, Leica Microsystems in microscopy and Molecular Devices in cell imaging. Agilent and Waters lead liquid chromatography and much of biopharma analytical testing; Illumina leads sequencing outside China, with MGI Tech the leading domestic alternative in China; Sartorius competes with Cytiva in bioreactors and filtration; Merck KGaA supplies bioprocess systems through MilliporeSigma; Bruker leads high-end mass spectrometry and NMR; and Bio-Rad, Revvity, Shimadzu, Tecan, Hamilton and 10x Genomics complete the field. Scale wins in bioprocessing and chromatography, where a validated platform is rarely displaced, while in genomics and single-cell analysis technology leadership turns over every few years.

How far could biotechnology instruments reach by 2035 if academic budgets fall or GLP-1 plants multiply?

The base case carries 4.3% growth in units and 1.8% growth in price for a 6.18% revenue CAGR and USD 75.7 billion in 2035. In the slower scenario, US research budgets are cut, China’s substitution of domestic instruments accelerates and biotech funding stays weak, so the legs fall to 2.5% and 0.6% and the biotechnology instruments market reaches about USD 56.5 billion. In the faster scenario, GLP-1 and cell therapy capacity is built on schedule, academic budgets recover and automation spreads faster, lifting the legs to 5.8% and 2.8% and carrying the market to about USD 96.3 billion. Each 1-point change in unit growth moves the 2035 figure by roughly USD 7.58 billion. Published estimates for the category run between 5% and 8% a year; the Douglas figure sits inside that band because strong bioprocess growth is offset by slower academic and China demand.

Douglas Exclusive: the biotechnology instruments installed-base replacement model

The biotechnology instruments installed-base replacement model counts, by category and region, the instruments in service, their age, typical replacement cycle and the share bought by pharma, academic, contract and other labs, and converts that into replacement units due each year alongside new-capacity demand from announced biologics plants. A vendor, investor or lab procurement team can see which categories face a replacement wave, how exposed each is to academic funding and China, and where new-plant demand will outrun replacement. Douglas Insights updates the model as vendors report results and new plants are announced.

Methodology and receipts: how do 452,000 instruments add up to USD 41.6 billion?

Douglas Insights built the biotechnology instruments model bottom-up from units and prices across 7 instrument categories, 4 buyer groups and 5 regions. Units were derived from installed bases and replacement cycles, new biologics and CDMO capacity, research funding and laboratory counts; prices were set by category from list prices and realised selling prices. Totals were reconciled against the instrument revenue disclosed by 12 listed suppliers, including Thermo Fisher’s USD 44.6 billion and Danaher’s USD 24.6 billion 2025 group revenue, after removing consumables, services and diagnostics. The receipts are 452,000 units times USD 92,000 for 2025, 4.3% unit growth and 1.8% price growth to 2035.

Sources

1. Thermo Fisher Scientific Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results (2026)
2. Danaher Corporation Danaher Reports Fourth Quarter and Full Year 2025 Results (2026)
3. European Commission, DG Health and Food Safety EudraLex Volume 4: EU Guidelines for Good Manufacturing Practice (2025)
4. U.S. Food and Drug Administration FDA Drug Approvals and Databases (2026)